Results

Total Results: 1,220 records

Showing results for "adverse events".
Users also searched for: patient safety indicators

341. Template for Reports Developed (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/allergy-seasonal_research-protocol.pdf
     March 08, 2012 - events. … events resulting from systemic absorption, such as impaired bone growth, reduced height, suppression … events in SAR research. … Additionally, systematic reviews and meta-analyses that specifically assess adverse events associated … events, and results.

342. Standardized Library of Asthma Outcome Measures (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/white-paper-library-asthma.pdf
     April 01, 2019 - Relationships between events raise a challenge because relationships are often not directly asserted … • FHIR for additional relevant events: These might include procedures, encounters, etc. … • Temporal aspects for all events: These allow for inferred relationships. 3 Approach … Counted as number of events per patient in a 12-month reporting period. … Events of Interest Medication adverse events Adverse events related to asthma medications.

343. Peripheral-Artery-Disease-Treatment Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-artery-disease-treatment_executive.pdf
     May 01, 2013 - is the comparative effectiveness of aspirin and other antiplatelet agents in reducing the risk of adverse … What are the significant safety concerns associated with each treatment strategy (e.g., adverse drug … What are the significant safety concerns associated with each treatment strategy (e.g., adverse drug … What are the significant safety concerns associated with each treatment strategy (e.g., adverse drug … Some RCTs reported adverse events such as rash and wound leak.

344. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatitis-c_research-protocol.pdf
     November 30, 2011 - dosages and durations of treatment according to various factors. 10 A common (50 to 60 percent) adverse … In addition, psychiatric, gastrointestinal, dermatological, and hematologic adverse effects underlie … effects of intervention(s)  Harms from antiviral treatment, including withdrawals due to adverse … events, serious adverse events such as severe neutropenia, psychological adverse events, flu-like … symptoms, and hematological adverse events Timing and Setting: No minimum timing and all settings

345. Comparative Effectiveness of Strategies to De-escalate Aggressive Behavior in Psychiatric Patients in Acute Care Settings (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/aggression_executive.pdf
     October 01, 2016 - One RCT43 examined three possible harms: drug-related adverse effects; incidence of abnormal QT (QRS … flunitrazepam, no statistical testing reported (3 vs. 3, p=NR).48 Drug-related adverse events 91 … Few overall treatment-emergent adverse events with olanzapine vs. risperidone vs. haloperidol, p … =NR.72 Adverse events considered related to primary antipsychotic medication 558 Insufficient … No significant difference in discontinuation due to clinically significant adverse events with olanzapine

346. Treatment of Depression in Children and Adolescents: A Systematic Review - Evidence Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/Evidence%20Summary_0_0.pdf
     April 01, 2020 - • However, SSRIs may be associated with a higher risk of serious adverse events and with a higher … Studies that defined serious adverse events generally used FDA’s definition, that is, events resulting … adverse events. … Not all harm-related adverse events are SAEs. … and children with MDD and an increased risk of withdrawals due to adverse events in adolescents with

347. Vitamin-D-Calcium-Protocol-130611 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/vitamin-d-calcium_research-protocol.pdf
     September 13, 2013 - stratify the findings of the previous review, as well as any newly included studies on efficacy and adverse … or symptoms  Cerebrovascular events  Peripheral vascular events or symptoms  Cardiovascular death … strength Source: www.effectivehealthcare.ahrq.gov Published online: June 10, 2013 4 o Adverse … mortality  Cancer and cancer-specific mortality  Renal outcomes  Soft tissue calcification  (Other) adverse … For upper limit (adverse event [AE]) outcomes, we will include any adverse effects of high intake in

348. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND__0250_05-20-2010.pdf
     January 01, 2010 - intervention, harm(s) of intervention, stroke (both hemorrhagic and thromboembolic), other thromboembolic events … (deep vein thrombosis, pulmonary embolism), bleeding events, mortality, quality of life Atrial … Further, the associated hemodynamic and thromboembolic adverse events are a source of increasing cost

349. Executive Summary_Comparative Effectiveness Review No. 259: Partial Breast Irradiation for Breast Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-259-partial-breast-irradiation-executive-summary.pdf
     January 01, 2023 - • Acute adverse events (AEs) were significantly fewer with PBI compared with WBI, with no apparent … This highlights the need to investigate outcomes of PBI among patients with adverse risk factors. … These advancements result in improved dose homogeneity that may lower the risk for adverse events. … PBI is associated with fewer acute adverse effects, but the risk of IBR among patients treated with … PBI who have adverse clinical or pathologic features is unclear.

350. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/mat-retention-strategies-rapid-review-1.pdf
     August 01, 2020 - , 6 of whom were in the contingency group.15 The adverse events included one lethal opioid overdose … One RCT reported that 12 adverse events occurred in a study of 82 participants (15% overall; 17% in … events, ranging from serious fatal and nonfatal adverse events to adverse events presumed secondary … All studies reported nonserious adverse events at XR-naltrexone and XR-buprenorphine injection sites … KQ2: The number of adverse events was similar between groups, and no severe adverse events in either

351. Head-Neck-Cancer-Update Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/head-neck-cancer-update_executive.pdf
     December 01, 2014 - What is the comparative effectiveness of 3DCRT, IMRT, SBRT, and PBT regarding adverse events and QOL … Outcomes Outcomes for Key Questions 1, 3, and 4 included— • Final outcomes: QOL and adverse events, … Also, adverse events (e.g., radiation-associated xerostomia and salivary dysfunction, dysphagia, mucositis … Criteria for Adverse Events) is necessary to permit accurate assessment of the relative benefits and … Evidence was insufficient to draw relative conclusions on survival or tumor control; adverse events

352. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1412.pdf
     October 01, 2015 - events. … events could pose barriers to pirfenidone and nintedanib diffusion. … events could pose barriers to pirfenidone and nintedanib diffusion. … However, two clinical experts stated that adverse events could reduce patient acceptance.41,47 One … events.

353. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine_research-protocol.pdf
     December 06, 2010 - Many questions remain about the risks of these agents across a spectrum of adverse events—from relatively … 3: For patients with RA, do drug therapies differ in harms, tolerability, patient adherence, or adverse … Morbidity, mortality, and other serious adverse events ii. Tolerability iii. Adherence iv. … Other adverse effects • Timing: Minimum of 3 months of follow-up • Settings: Primary care … Also, adverse events may occur at any point after the treatment is received. IV. Methods A.

354. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-future_research.pdf
     March 01, 2012 - events (primarily cough). … ACE inhibitor or ARB) Withdrawals due to adverse events: High (ACE inhibitor vs. … events. … In addition, adverse events (including, but not limited to, weight gain, impaired renal function, angioedema … These studies reported additional data on blood pressure lowering, adverse events, and cough, but with

355. EHC Research Protocol: Management of Colonic Diverticulitis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diverticulitis-research-protocol.pdf
     January 01, 2019 - events, side effects of interventions (any time frame) o Hospitalization comparison:  Hospital-based … infections and other harms o Antibiotics comparisons:  Side effects/adverse events attributable … events related to procedures, including bleeding and catheter infections  Need for second procedures … o N≥30/arm* • Single group studies o Only for adverse events o N>100† • Longitudinal (Exclude: … events, and side effects of colonoscopy (e.g. perforation, bleeding) Modifiers/Subgroups of interest

356. Medication-Therapy-Management Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medication-therapy-management_executive.pdf
     November 01, 2014 - adverse drug events, many patients do not receive optimal pharmaceutical prescriptions. … drug events. … drug events or mortality (Table D). … drug events, prescriber confusion, and prescriber dissatisfaction. … events.

357. Untitled (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c_surveillance.pdf
     December 01, 2015 - adverse events, flu-like symptoms, rash) Intermediate outcomes •! … Found no difference in withdrawals due to adverse events. … No difference in risk of withdrawal due to adverse events. … Found no difference in withdrawals due to adverse events. … No difference in risk of withdrawal due to adverse events.

358. Untitled (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatitis-c_surveillance.pdf
     December 01, 2015 - adverse events, flu-like symptoms, rash) Intermediate outcomes •! … Found no difference in withdrawals due to adverse events. … No difference in risk of withdrawal due to adverse events. … Found no difference in withdrawals due to adverse events. … No difference in risk of withdrawal due to adverse events.

359. App-D-Surv-Report-3-Noninvasive-Nonpharma 0 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-3-noninvasive-nonpharma_0.xlsx
     January 01, 2022 - Exercise) Adverse Events Including Withdrawals Funding Source Quality Alqualo-Costa 2021 [Surveillance … NR, adj MD -0.1 (95% CI -0.4 to 0.6), p=0.7 NR NR No serious adverse events were observed This study … C Adverse events that the external safety officer approved the designation of possibly or definitely … they experienced minor adverse events. … 0/64); the 1 serious adverse events was a case of National Center for Complementary and Integrative

360. Systematic Review on Opioid Treatments for Chronic Pain: Surveillance Report 2 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/opioid-chronic-pain-surveillance-report-2.pdf
     April 01, 2022 - events, or cardiovascular adverse events (KQ 2b), there were no … associated with decreased risk of cardiovascular adverse events versus opioid agonists; there was … Harms and Adverse Events: a. … events, serious adverse events, overdose, substance misuse, substance use disorder related outcomes … Harms and Adverse Events: Key Question 3. Dosing Strategies: Key Question 4.